GLP-1 comparison
Mounjaro vs Ozempic
Different companies, different molecules, different receptors. Both are once-weekly injections approved for type 2 diabetes — and in the head-to-head trial, one produced meaningfully more A1C reduction and weight loss than the other.
Mounjaro
Tirzepatide — dual GIP + GLP-1
Two mechanisms in one molecule. In SURPASS-2, produced ~2× the weight loss and greater A1C reduction versus semaglutide 1 mg. Goes up to 15 mg.
Ozempic
Semaglutide — GLP-1 only
Longer real-world track record, cardiovascular outcomes data (SUSTAIN-6), and typically easier US coverage. Caps at 2.0 mg for T2D.
Side by side
Mounjaro
Tirzepatide, Eli Lilly
Ozempic
Semaglutide, Novo Nordisk
Highlighted cells indicate the clearer choice on that row. Sourced from FDA prescribing information and pivotal trials — see references below.
How much would you lose on each?
Project your expected weight loss on tirzepatide or semaglutide from your own weight and dose.
Which one is right for you?
You want the strongest A1C and weight response
SURPASS-2 favored tirzepatide (Mounjaro). If your A1C is high, or weight loss matters alongside diabetes control, Mounjaro is where the head-to-head evidence points.
You want proven cardiovascular protection
Semaglutide (Ozempic) has SUSTAIN-6 data showing a 26% relative reduction in major cardiovascular events in high-risk T2D. Tirzepatide's CV outcome trial is still enrolling.
Cost or coverage is the deciding factor
Both list around $1,000–$1,070 monthly. Coverage varies by plan; some cover one but not the other. Confirm coverage before you commit.
Related in your GLP-1 journey
Full GLP-1 hub →Frequently Asked Questions
Sources
- Mounjaro (tirzepatide) Prescribing InformationU.S. Food & Drug Administration (FDA). 2024.
- Ozempic (semaglutide) Prescribing InformationU.S. Food & Drug Administration (FDA). 2025.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
Tool Information
August 5, 2026
Dr. Jaydeep Sanghani
Meet Akabari

Dr. Jaydeep Sanghani
MBBS, MD, DNB(Anaesth.), PDCC(CCM), DrNB(CCM)
AIIMS Bhubaneswar · AIIMS Rishikesh
Critical care specialist and anesthesiologist with advanced training from AIIMS. Reviews health calculators at Calqulate to ensure medical accuracy and evidence-based standards.
